Literature DB >> 12607837

Physical aspects of yttrium-90 microsphere therapy for nonresectable hepatic tumors.

Mehrdad Sarfaraz1, Andrew S Kennedy, Zong J Cao, Gregory D Sackett, Cedric X Yu, Martin A Lodge, Ravi Murthy, Bruce R Line, David A Van Echo.   

Abstract

Administration of yttrium-90 microspheres via the hepatic artery is an attractive approach to selectively deliver therapeutic doses of radiation to liver malignancies. This procedure allows delivering radiation absorbed doses in excess of 100 Gy to the tumors without significant liver toxicity. The microsphere therapy involves different specialties including medical oncology, radiation oncology, nuclear medicine, interventional radiology, medical physics, and radiation safety. We have treated 80 patients with nonresectable hepatic tumors with yttrium-90 microspheres during the past two years on an institutional study protocol. The nominal radiation absorbed dose to the tumor in this study was 150 Gy. Required activity was calculated based on the nominal radiation absorbed dose and patient's liver volume obtained from the CT scan, assuming a uniform distribution of the microspheres within the liver. Microspheres were administered via a catheter placed into the hepatic artery. The actual radiation absorbed doses to tumors and normal liver tissue were calculated retrospectively based on the patient's 99mTc-MAA study and CT scans. As expected, the activity uptake within the liver was found to be highly nonuniform and multifold tumor to nontumor uptake was observed. A partition model was used to calculate the radiation absorbed dose within each region. For a typical patient the calculated radiation absorbed doses to the tumor and liver were 402 and 118 Gy, respectively. The radiation safety procedure involves confinement of the source and proper disposal of the contaminated materials. The average exposure rates at 1 m from the patients and on contact just anterior to the liver were 6 and 135 uSv/h, respectively. The special physics and dosimetry protocol developed for this procedure is presented.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12607837     DOI: 10.1118/1.1538235

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  11 in total

Review 1.  Radiotherapy and wound healing.

Authors:  Emma-Louise Dormand; Paul E Banwell; Timothy E E Goodacre
Journal:  Int Wound J       Date:  2005-06       Impact factor: 3.315

Review 2.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

3.  Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.

Authors:  Marta Cremonesi; Mahila Ferrari; Giovanni Paganelli; Annalisa Rossi; Marco Chinol; Mirco Bartolomei; Gennaro Prisco; Giampiero Tosi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

Review 4.  Transcatheter intraarterial therapies: rationale and overview.

Authors:  Robert J Lewandowski; Jean-Francois Geschwind; Eleni Liapi; Riad Salem
Journal:  Radiology       Date:  2011-06       Impact factor: 11.105

5.  Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.

Authors:  Robert J Lewandowski; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

6.  Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment.

Authors:  Harshal Rajekar; Kashan Bogammana; Richard S Stubbs
Journal:  Int J Hepatol       Date:  2011-11-15

Review 7.  A systematic review on the safety and effectiveness of yttrium-90 radioembolization for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Zhongzhi Jia; Guomin Jiang; Feng Tian; Chunfu Zhu; Xihu Qin
Journal:  Saudi J Gastroenterol       Date:  2016 Sep-Oct       Impact factor: 2.485

8.  Towards automated planning for unsealed source therapy.

Authors:  Eduard Schreibmann; Tim Fox
Journal:  J Appl Clin Med Phys       Date:  2012-07-05       Impact factor: 2.102

9.  Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity.

Authors:  Jonas Högberg; Magnus Rizell; Ragnar Hultborn; Johanna Svensson; Olof Henrikson; Johan Mölne; Peter Gjertsson; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2015-04-25

Review 10.  Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective.

Authors:  Marta Cremonesi; Carlo Chiesa; Lidia Strigari; Mahila Ferrari; Francesca Botta; Francesco Guerriero; Concetta De Cicco; Guido Bonomo; Franco Orsi; Lisa Bodei; Amalia Di Dia; Chiara Maria Grana; Roberto Orecchia
Journal:  Front Oncol       Date:  2014-08-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.